NCT02656849View on ClinicalTrials.gov

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 29, 2016

Primary Completion Date

October 31, 2019

Study Completion Date

May 31, 2023

Conditions

Solid Tumor

Interventions

DRUG

BAY 1000394

Trial Locations (1)

02115

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Bayer

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT02656849 - BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors | Biotech Hunter | Biotech Hunter